0.727
Schlusskurs vom Vortag:
$0.7034
Offen:
$0.725
24-Stunden-Volumen:
25,907
Relative Volume:
0.25
Marktkapitalisierung:
$5.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-2.72M
KGV:
-1.5143
EPS:
-0.4801
Netto-Cashflow:
$-4.88M
1W Leistung:
-1.36%
1M Leistung:
+20.07%
6M Leistung:
-33.30%
1J Leistung:
-28.73%
Mustang Bio Inc Stock (MBIO) Company Profile
Firmenname
Mustang Bio Inc
Sektor
Branche
Telefon
(781) 652-4500
Adresse
95 SAWYER RD, WALTHAM, NY
Compare MBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
MBIO
Mustang Bio Inc
|
0.727 | 5.59M | 0 | -2.72M | -4.88M | -0.4801 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mustang Bio Inc Stock (MBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-05-18 | Eingeleitet | BTIG Research | Buy |
| 2020-10-02 | Eingeleitet | B. Riley FBR | Buy |
| 2019-11-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-08-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-06-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-12-21 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Mustang Bio Inc Aktie (MBIO) Neueste Nachrichten
CNET Q3 2011 Earnings: EPS Misses by 65.4% Amid Uncertain Revenue DisclosureEarnings Growth Analysis - newsline.com
MBIO Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
ADXN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
CCL Q1 2026 Earnings: EPS Surpasses Estimates by 7.3%, Shares Gain 2.5%Cash Flow Report - newsline.com
MBIO Should I Buy - Intellectia AI
Spring Valley Acquisition Corp. III (SVAC) Holds Near Support Amid Modest DeclineRTH Profile - newsline.com
Mustang Bio (MBIO) Moves Higher, Testing Key Resistance at $0.83Analyst Downgrade Signals - newsline.com
Water Utility Fined £1.8 Million Over Parasite Outbreak in DevonProfit Announcement - newsline.com
JATT Price Today: JATT II Acquisition Corp. Stock Price, Quote & Chart | MEXC - MEXC
Mustang Bio Q4 2024 Earnings: Massive EPS Miss Highlights Cash Burn and Clinical Progress UncertaintyCapex Guidance - newsline.com
MSN Money - MSN
Mustang Bio (MBIO) Q4 2024 Earnings: Wider-Than-Expected Losses Offset by Positive Stock Movement Amid Pipeline FocusGuidance Accuracy Score - newsline.com
WaFd Inc. (WAFD) Q1 2026 Earnings: EPS Tops Estimates; Small Decline in StockFree Cash Flow Trends - The Legal Advocate
Real Asset Acquisition Corp. Unit (RAAQU) Holds Steady Near Support as Consolidation Phase ContinuesInvestment Factor - The Legal Advocate
Is Mustang Bio (MBIO) a Hidden Gem in the Microbiome Revolution, or a Risky Bet - Kavout
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Wider-than-Expected Loss Amid Pre-Revenue StageEarnings Miss Alert - newsline.com
Mustang Bio Inc. (MBIO) Gains 5.68% as Shares Approach Key Resistance at $0.70Merger Arbitrage - The Legal Advocate
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Severe EPS Miss Highlights Pre-Revenue Biotech Challenges - The Legal Advocate
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Massive EPS Miss Amidst No RevenueTangible Book Value - newsline.com
Mustang Bio (MBIO) Edges Higher: Biotech Stock Testing Key Resistance at $0.67Wyckoff Distribution - newsline.com
Varonis Systems (VRNS) Holds Steady Amid Minor Dip; Key Levels in FocusHull Moving Average - The Legal Advocate
SKYX Platforms Stock Slides: Support Test at $1.05 as Bearish Pressure MountsIV Rank - newsline.com
OSBC Q1 2026 Earnings: Earnings Miss Estimates Amid Narrowing MarginsTrough Earnings Signal - newsline.com
Universal Corporation (UVV) Q1 2026 Results Miss Estimates — EPS $1.32 vs $1.94Weak Earnings Momentum - The Legal Advocate
Mustang Bio (MBIO) Slides -1.27% as Selling Pressure Mounts 2026-05-18AI Expert Picks - Newser
What Mustang Bio (MBIO)'s -0.88% Decline Means for Investors 2026-05-18Stock Analysis Community - Newser
Mustang Bio stock (US62815P1003): restructuring progress keeps spotlight on cash and pipeline - AD HOC NEWS
Mustang Bio stock (US62815P1003): restructuring moves and Nasdaq relisting plan put focus back on ce - AD HOC NEWS
Brigade Enterprises FY26 Pre-Sales Dip 5% to Rs 7,424 Crore on Approval Delays; Board Recommends 1:3 Bonus IssueEarnings Outlook Update - The Legal Advocate
Mustang Bio’s Cancer Therapy Bets Face A Nasdaq Countdown - Finimize
TradingKey - TradingKey
Mustang Bio (NASDAQ: MBIO) reports Q1 loss, limited cash and Nasdaq bid-price risk - Stock Titan
Mustang Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
What Booz Allen (BAH) is doing to win in its industry | Q1 2026: EPS Tops ViewsConsensus Beat Rate - The Legal Advocate
SERA (Sera Prognostics) tops Q4 2025 EPS estimates, shares fall 2.51% on lack of revenue visibility.GAAP Earnings Report - The Legal Advocate
MUSTANG BIO, INC. (MBIO) - MSN
CAR-T Cell Therapy Market Will Generate Booming Growth Opportunities to 2030 | Novartis, Johnson & Johnson Services, Mustang, Sorrento Therapeutics, Fate Therapeutics etc. - industrytoday.co.uk
Finanzdaten der Mustang Bio Inc-Aktie (MBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mustang Bio Inc-Aktie (MBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chill Adam J. | Director |
Dec 30 '25 |
Sale |
0.95 |
4 |
4 |
375 |
| Jin David | Director |
Dec 30 '25 |
Buy |
0.96 |
247 |
238 |
286 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):